Soliqua · DIN 02478293 · 100U/mL & 33 mcg/mL · injection solution-pre-filled pen 5x3mL Pk
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Soliqua · DIN 02478293
Manufacturer: Sanofi-Aventis Canada Inc.; listing date 2019-12-20
Health Canada: Marketed since 2018-09-12 · brand SOLIQUA · ATC A10AE54 INSULIN GLARGINE AND LIXISENATIDE, A10AE54 INSULIN GLARGINE AND LIXISENATIDE · form Solution · route Subcutaneous · ingredients LIXISENATIDE 33 MCG/ML, INSULIN GLARGINE 100 UNIT/ML · company Sanofi-aventis canada inc · schedule Schedule d, Prescription
Soliqua: Formulary list price $206.60 per unit (the source does not state the unit; exact figure $206.6000). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02478293)
Source record
DIN 02478293: Soliqua
Raw flags: insOH=Y, sec3=Y
Item: 682006005; group id 758; item number 1863; lccId None; manufacturer id SAC
Source form: Inj Sol-Pref Pen 5x3mL Pk; strength: 100U/mL & 33mcg/mL
Recorded listing: General benefit; diabetes medication flag
Source prices (unrounded): $206.6000; ministry $206.6000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02478293
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96906
Therapeutic Notes (formulary)
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 60 units daily) in combination with metformin.
Shortage status: resolved shortage (ended August 3, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02478293
Shortage record checked October 6, 2026